RNAi沉默CXCR7对人结肠癌细胞SW620特异性靶向抑制的实验研究

doi:10.13523/j.cb.20140203

中国生物工程杂志

2014, Vol. 34

Issue (2): 14-20 DOI: 10.13523/j.cb.20140203

研究报告

RNAi沉默CXCR7对人结肠癌细胞SW620特异性靶向抑制的实验研究

王鑫, 陈玲, 孙飞, 陆航

辽宁医学院附属第一医院锦州 121000

Experimental Study of Specific Targeted Inhibition from RNAi Silencing CXCR7 to Human Colon Cancer Cell SW620

WANG Xin, CHEN Ling, SUN Fei, LU Hang

The First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, China

全文: PDF(1457 KB) HTML

摘要： 目的：探讨慢病毒介导的CXCR7-shRNA转染人结肠癌细胞株SW620后对CXCR7蛋白表达的影响。方法：（1）设计并合成CXCR7的3对shRNA序列及1对阴性对照序列，与pSilencer^TM 4.1系统合成构建重组慢病毒载体，转染HEK293T细胞包装病毒并检测滴度；（2）将3种重组慢病毒载体及阴性对照分别感染人结肠癌细胞SW620，RT-PCR检测CXCR7 mRNA的表达情况，测定沉默效率，筛选沉默效率最高的一组CXCR7-shRNA作为后续实验表达载体；（3）MTT法检测转染CXCR7-shRNA对SW620细胞生长增殖的影响；（4）通过细胞划痕实验检测转染CXCR7-shRNA对SW620细胞侵袭迁移能力的影响；（5）Western blot检测转染CXCR7-shRNA对SW620细胞蛋白表达情况。结果：（1）测序证实3对慢病毒载体及1对阴性对照载体均包装成功，滴度分别为3.16×10⁸TU/ml、4.27×10⁸TU/ml、3.93×10⁸TU/ml和2.95×10⁸TU/ml；（2）3组慢病毒载体转染SW620细胞后，CXCR7 mRNA的表达量均较阴性对照组明显降低（P<0.05），其中CXCR7-shRNA-1对CXCR7的抑制率明显高于其他两组（P<0.05）；（3）CXCR7-shRNA-1转染SW620后，肿瘤细胞的增殖程度显著减少，与空白组相比有显著性差异（P<0.05）；（4）SW620细胞在划痕24h后，空白对照组和实验组的细胞迁移指数（MI）分别为（49.92±6.41）%和（29.13±5.38）%，有统计学意义（P<0.05），划痕48h后，对照组与实验组的MI分别为（96.52±7.44）%和（72.03±8.29）%，有统计学意义（P<0.05）；（5）CXCR7-shRNA-1转染SW620细胞后，与空病毒载体组、空白组相比，CXCR7蛋白表达量明显降低，具有统计学意义（P<0.05）。结论：CXCR7-shRNA慢病毒表达载体转染SW620细胞后可有效下调CXCR7 mRNA和蛋白的表达水平并能够抑制肿瘤细胞的增殖与迁移，为下一步研究以CXCR7/CXCL12生物学轴为靶点的结直肠癌慢病毒基因沉默治疗打下了良好的基础，为结直肠癌的基因治疗提供了新方向。

关键词： 结直肠癌; CXCR7; CXCL12; 重组慢病毒载体; RNAi

Abstract: Object: To investigate the change of CXCR7 protein expression after CXCR7-shRNA transfered into human colon cancer cell SW620 which is lentivirus-mediated. Methods: 1. To design and synthesis three shRNA sequence and one negative control sequence of CXCR7. To synthesis and construct recombinant lentiviral vector by pSilencerTM 4.1 system and CXCR7. To transfer the vector into HEK293T cell for packaging viral and to detect titer. 2. To transfer the three different recombinant lentiviral vector and one negative control vector into human colon cancer cell SW620.To detect expression and silence efficiency of CXCR7 mRNA by RT-PCR. The group expressing the best silence efficiency of CXCR7-shRNA is selected as expression vector for next experiment. 3. To detect the change of SW620 cell proliferation after CXCR7-shRNA transfection by MTT. 4. To detect the change of SW620 cell invasion and migration after CXCR7-shRNA transfection by cell scratching experiment. 5. To detect the SW620 protein expression after CXCR7-shRNA transfection by Western blot. Results: 1. Packaging the three different recombinant lentiviral vector and one negative control vector is successful by sequencing and titer is 3.16×10⁸TU/ml, 4.27×10⁸TU/ml, 3.93×10⁸TU/ml, 2.95×10⁸TU/ml respectively. 2. Expression of CXCR7 mRNA in three positive group is lower than negative control group after transfection(P<0.05).The inhibition rate of CXCR7-shRNA-1 to CXCR7 is higher than the another group. 3. The tumor cell proliferation is reduced after CXCR7-shRNA-1 transfection into SW620 cell and there was significant difference comparing to control group(P<0.05). 4. The migration index of control group and positive group are (49.92±6.41)%,(29.13±5.38)% respectively 24 hours after cell scratching experiment and it has statistical significance (P<0.05).The migration index of control group and positive group are (96.52±7.44)%,(72.03±8.29)% respectively 48h hours after cell scratching experiment and it has statistical significance (P<0.05). 5. Expression of CXCR7 is reduced after transfection into SW620 cell comparing to empty virus vector group and control group and it has statistical significance (P<0.05). Conclusion: Expression of CXCR7 mRNA and CXCR7 protein is down-regulated effectively after CXCR7-shRNA recombinant lentiviral vector transfection into SW620 cell and proliferation and migration of tumor cell is inhibited effectively. It is a good foundation on next study of colon cancer RNAi therapy with lentiviral which target CXCR7/CXCL12 biological axis. And it is a new direction for colon cancer gene therapy.

Key words: Colon cancer CXCR7 CXCL12 Recombinant lentiviral vector RNAi

收稿日期: 2013-10-17 出版日期: 2014-02-25

ZTFLH:

Q819

基金资助: 辽宁省自然科学基金资助项目（201102124）

通讯作者: 陆航 E-mail: jzluhang2013@126.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王鑫
	陈玲
	孙飞
	陆航

引用本文:

王鑫, 陈玲, 孙飞, 陆航. RNAi沉默CXCR7对人结肠癌细胞SW620特异性靶向抑制的实验研究[J]. 中国生物工程杂志, 2014, 34(2): 14-20.

WANG Xin, CHEN Ling, SUN Fei, LU Hang. Experimental Study of Specific Targeted Inhibition from RNAi Silencing CXCR7 to Human Colon Cancer Cell SW620. China Biotechnology, 2014, 34(2): 14-20.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20140203 或 https://manu60.magtech.com.cn/biotech/CN/Y2014/V34/I2/14

[1] 王宁, 孙婷婷, 郑荣寿, 等. 中国2009年结直肠癌发病和死亡资料分析. 中国肿瘤, 2013, 22(7): 515-520. Wang N,Sun T T ,Zheng R S ,et al.An analysis of incidence and mortality of colorectal cancer in China,2009. China Cancer,2013,22(7):515-520.
[2] Li F Y, Lai M D. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B, 2009, 10(3): 219-229.
[3] Szajda S D, Jankowska A, Zwierz K. Carbohydrate markers in colon carcinoma. Dis Markers, 2008, 25(4-5): 233-242.
[4] Lu H, Sun H Z, Li H, et al. The clinicopathological significance of Bmi-1 expression in pathogenesis and progression of gastric carcinomas. Asian Pac J Cancer Prev, 2012, 13(7): 3437-3441.
[5] Frieden T R, Myers J E, Krauskopf M S, et al. A public health approach to winning the war against cancer. Oncologist, 2008, 13(12): 1306-1313.
[6] Wang Y, Li G, Stanco A, et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron, 2011, 69(1):61-76.
[7] Liu L, Zhao X, Zhu X, et al. Decreased expression of miR-430 promotes the development of bladder cancer via the upregulation of CXCR7. Mol Med Rep, 2013, 8(1):140-146.
[8] Schanz A, Baston-Bust D, Krussel J S, et al. CXCR7 and syndecan-4 are potential receptors for CXCL12 in human cytotrophoblasts. J Reprod Immunol, 2011, 89(1):18-25.
[9] Xue T C, Chen R X, Ren Z G, et al. Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopontin. Oncol Rep, 2013, 30(1):105-110.
[10] Zeng Z, Zhang C, Chen J. Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts. J Bone Miner Metab, 2013, 31(4): 409-416.
[11] Liu L, Zhang N, Liu J, et al. Lentivirus-mediated siRNA interference targeting SGO-1 inhibits human NSCLC cell growth. Tumour Biol, 2012, 33(2): 515-521.
[12] Ying J, Xu Q, Zhang G, et al. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med Oncol, 2012, 29(3): 1716-1722.
[13] Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem, 2005, 280(42): 35760-35766.
[14] Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem, 2008, 283(7): 4283-4294.
[15] Miao Z, Luker K E, Summers B C, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A, 2007, 104(40): 15735-15740.
[16] Raggo C, Ruhl R, McAllister S, et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res, 2005, 65(12): 5084-5095.
[17] Elbashir S M, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev, 2001, 15(2): 188-200.
[18] Mohan R R, Rodier J T, Sharma A. Corneal gene therapy: basic science and translational perspective. Ocul Surf, 2013, 11(3): 150-164.
[19] Miyata Y, Iwata T, Ohba K, et al. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res, 2006, 12(23):6998-7003.

[1]	陈露,黄茂,彭棋,赵佳丽,谢佳卿,林璐,户丽君,黄逸云,胡琴,周兰. S100A6通过巨噬细胞促结直肠癌细胞增殖的作用及机制 ^*[J]. 中国生物工程杂志, 2019, 39(4): 1-7.
[2]	代爽, 赵青青, 邱峰. PEI-壳聚糖在结肠癌细胞CD133⁺梯度表达的转染研究[J]. 中国生物工程杂志, 2016, 36(6): 32-38.
[3]	孙晖, 李雪茹, 查何, 段亮, 袁世梅, 李欢, 李爱芳, 谷月, 周兰. *外源性S100A6蛋白对人结直肠癌细胞S100A6基因转录的影响及机制探讨*[J]. 中国生物工程杂志, 2016, 36(1): 14-22.
[4]	任琴, 郭志鸿, 王亚军, 谢忠奎, 王若愚. RNA干扰及其在增强作物抵抗有害真核生物研究中的应用[J]. 中国生物工程杂志, 2015, 35(6): 80-89.
[5]	薛玉文, 李铁军, 周家名, 陈莉. 多靶向RNA干扰技术在基因治疗中的应用与前景[J]. 中国生物工程杂志, 2015, 35(1): 75-81.
[6]	李玉强, 朱志图, 王巍, 李谌, 徐娜, 王钰, 李男, 孙宏治. *RNA干扰NUP88基因对人乳腺癌MCF-7细胞生长及侵袭力的影响*[J]. 中国生物工程杂志, 2014, 34(9): 31-39.
[7]	蒋婷婷, 温晓霞, 陈尧. *沉默c2orf68基因对结直肠癌细胞增殖的影响*[J]. 中国生物工程杂志, 2014, 34(2): 7-13.
[8]	赵蕊, 吕静野, 黄海丽, 严启滔. CHD5基因RNAi慢病毒载体的构建及其对结直肠癌细胞生物学功能的影响[J]. 中国生物工程杂志, 2012, 32(05): 7-11.
[9]	侯静波, 孟佳, 张一娜. 过表达的趋化因子CXCL12通过PI3K/Akt途径促进骨髓基质干细胞Connexins的表达[J]. 中国生物工程杂志, 2012, 32(04): 18-21.
[10]	李培培, 游雷鸣, 罗俊, 鄂魏, 蒋志政, 郅玉宝, 张改平, 王爱萍. 鸡源细胞基因沉默及快速筛选的实用型双标记RNAi载体[J]. 中国生物工程杂志, 2011, 31(11): 81-89.
[11]	秦俊文, 谢琪璇, 蔡冬青, 秋山泰身, 井上纯一郎. shRNA慢病毒质粒的构建技巧[J]. 中国生物工程杂志, 2011, 31(03): 124-127.
[12]	叶梅霞刘军梅李昊崔东清王静澄张志毅安新民. amiRNAi-实现高效稳定的特异基因沉默新方法[J]. 中国生物工程杂志, 2010, 30(08): 118-125.
[13]	高旭东胡明明朱运峰. 下调LINE-1编码蛋白ORF-1p对肺癌细胞A549生物学特征的影响[J]. 中国生物工程杂志, 2010, 30(06): 14-20.
[14]	王彪刘照亮林菊丽单秀英王美水张声鲁开化. Ang2、Tie2基因的RNA干扰及其在体外抑制血管生成的作用[J]. 中国生物工程杂志, 2010, 30(04): 20-25.
[15]	梁倩倩张金文魏玉杰王旺田何庆祥雷耀湖. 野生罂粟COR、BBE基因片段融合及其RNAi载体构建[J]. 中国生物工程杂志, 2009, 29(11): 41-47.

Viewed

Full text

Abstract

Cited

Shared

Discussed